Tettey Abraham, Jiang Yujie, Li Xiaohui, Li Ying
Department of Pharmacology, School of Pharmaceutical Science, Central South University, Changsha, China.
Hunan Key Laboratory for Bioanalysis of Complex Matrix Samples, Changsha, China.
Front Pharmacol. 2021 Nov 12;12:767002. doi: 10.3389/fphar.2021.767002. eCollection 2021.
Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.
肺动脉高压（PAH）是一种严重疾病，会导致平均肺动脉压升高、右心室肥厚并最终导致死亡。近年来的研究为其临床管理提供了多种治疗选择，但即使在治疗情况下高死亡率仍然是一个巨大挑战，这归因于复杂的病理生理学。临床和非临床实验研究表明，一氧化氮（NO）途径是PAH病理生理学的关键途径之一。许多用于管理PAH的基本药物作用于该途径，突出了其在PAH中的重要作用。同时，几种针对NO途径的新型化合物具有成为未来治疗药物的巨大潜力。此外，发现NO途径与其他关键途径相互作用。了解这种相互作用可能有助于发现能提供更好临床结果的新药。
